Abbott reported that Diagnostics revenue rose 6% year over year to $2.18 billion in Q1 2026, marking the first quarter of results after completion of its Exact Sciences acquisition. Core laboratory revenue increased 8% to $1.27 billion, supported by growth across the US, Europe, and Latin America. The company said rapid and molecular diagnostics declined 7% to $812 million, driven by lower demand for respiratory virus tests. Cancer diagnostics revenue totaled $96 million, newly added to Abbott’s balance sheet post-acquisition, with comparable growth of 13% reported. Overall Q1 revenue climbed 8% to $11.16 billion, beating analysts’ average estimate of $11.0 billion. Abbott also reported adjusted EPS of $1.15, while net earnings fell year over year to $1.08 billion due to higher spending. Abbott’s R&D rose to $767 million and SG&A jumped 22% to $3.74 billion, underscoring integration and operating-cost pressure even as diagnostics grew.